Evidence map›Paper›PMID 41697125›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

HSP90AB1-Mediated Ubiquitin-Proteasome Degradation of ITGBL1 Promotes Osteosarcoma Progression by Inhibiting Endoplasmic Reticulum Stress-Induced Autophagy.

Zhen Wang, Zixuan Guo, Chengwei Cao, Ziying Wang, Zifu Huang, Xiujuan Zhang, Yushu Zheng, Diankun She, Hao Zhu, Lingfeng Yu and 8 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zhen WangMedical School of Chinese PLA, Beijing, China.
Zixuan GuoMedical School of Chinese PLA, Beijing, China.
Chengwei CaoMedical School of Chinese PLA, Beijing, China.
Ziying WangMedical School of Chinese PLA, Beijing, China.
Zifu HuangMedical School of Chinese PLA, Beijing, China.
Xiujuan ZhangDepartment of Cell Engineering, Beijing Institute of Biotechnology, Beijing, China.
Yushu ZhengMedical School of Chinese PLA, Beijing, China.
Diankun SheDepartment of Orthopedics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Hao ZhuInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
Lingfeng YuDepartment of Orthopedic Oncology, Shanghai Bone Tumor Institute, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xuelin ZhaoMedical School of Chinese PLA, Beijing, China.
Dongquan XiangSenior Department of Orthopedics, the Fourth Medical Centre, Chinese PLA General Hospital, Beijing, China.
Song LiaoSenior Department of Orthopedics, the Fourth Medical Centre, Chinese PLA General Hospital, Beijing, China.
Xin HeCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.
Xintong JiSchool of Medicine, Chongqing University, Chongqing, China.
Chengsheng WuCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.
Cheng-Xiong XuSchool of Medicine, Chongqing University, Chongqing, China.
Meng XuMedical School of Chinese PLA, Beijing, China.ORCID https://orcid.org/0009-0002-6679-7836

Funding

Chongqing Natural Science Foundation CSTB2022NSCQ-MSX0362National Defense Science and Technology Excellence Youth Science Fund Program 2022JCJQ-ZQ-018National Key Research and Development Program of China 2023YFB4706305National Natural Science Foundation of China 82573393
6 · The paper itself

Abstract

Osteosarcoma (OS) is one of the most malignant bone tumors in children and adolescents, but the molecular mechanisms of OS progression remain largely undefined. In this study, we demonstrate that Integrin subunit beta-like 1 (ITGBL1) is downregulated in OS tissues, and its downregulation correlates with poor prognosis in OS patients. Functional assays revealed that ITGBL1 inhibits OS cell growth, metastasis, and stemness, while promoting apoptosis. The in vitro and in vivo experiments further revealed that ITGBL1 activates endoplasmic reticulum (ER) stress by upregulating ROS, thereby triggering autophagy in OS cells. In addition, the downregulation of ITGBL1 in OS is partly attributed to the abnormal upregulation of HSP90AB1 (heat shock protein 90 alpha family class B1). Mechanistically, ITGBL1 interacts with HSP90AB1 which facilitates ITGBL1 degradation through K63-linked ubiquitination. Finally, through virtual screening and Co-IP, we identified ivermectin as a potent inhibitor of the HSP90AB1-ITGBL1 interaction, and treatment with ivermectin dramatically inhibited OS progression in vivo. In conclusion, we uncover a novel mechanism that promotes OS progression and identify a new candidate drug for the treatment of OS.

Indexed as

AutophagyBone NeoplasmsEndoplasmic Reticulum StressHSP90 Heat-Shock ProteinsIntegrin beta1OsteosarcomaProteasome Endopeptidase ComplexUbiquitinAnimalsCell Line, TumorDisease ProgressionFemaleHumansMaleMiceUbiquitinationHSP90AB1 protein, humanHSP90 Heat-Shock ProteinsIntegrin beta1Proteasome Endopeptidase ComplexUbiquitinAutophagyER stressHSP90AB1ITGBL1K63‐linked ubiquitinationOsteosarcoma

Identifiers

PMID41697125
PMCPMC13104077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.